Chinese NMPA Accepts Telix Pharmaceuticals' New Drug Application for Illuccix Prostate Cancer Imaging Agent
Tuesday, January 20, 2026
The Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has officially accepted the New Drug Application (NDA) for TLX591-Px, marketed as Illuccix®, a kit for the preparation of gallium-68 gozetotide injection used in prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging for prostate cancer. This acceptance represents a significant regulatory milestone for Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) and its strategic partner, Grand Pharmaceutical Group Limited, in the Greater China region.
Illuccix is Telix's lead commercial imaging product, already approved in multiple markets including the United States, Europe, and Australia. The submission in China was supported by results from a pivotal Phase 3 clinical study conducted specifically in Chinese patients, which successfully met its primary endpoint. The study demonstrated a positive predictive value of 94.8% in patients with biochemical recurrence of prostate cancer. Furthermore, PSMA-PET imaging with Illuccix led to a change in treatment management for 67.2% of patients, underscoring its clinical utility in informing precise therapeutic decisions.
This development aligns with Telix's broader strategy of geographic expansion into high-growth markets like China, where prostate cancer diagnoses are increasing at approximately 6% annually. The Chinese government's support for nuclear medicine infrastructure, including a surge in PET/CT scanner installations, positions Illuccix for substantial market potential upon approval. Kevin Richardson, Chief Executive Officer of Precision Medicine at Telix, emphasized that this is the first NDA filing for any Telix product in China, highlighting the strategic importance of the market for the company's precision medicine portfolio.
The partnership with Grand Pharmaceutical Group Limited facilitated the submission and will support ongoing regulatory interactions with the NMPA. If approved, Illuccix would seek a broad label covering multiple stages of prostate cancer care, from initial staging to biochemical recurrence and treatment response assessment. This would enable clinicians in China to leverage advanced PSMA-PET imaging, which has demonstrated comparable performance to international studies, even in patients with very low prostate-specific antigen (PSA) levels and across diverse metastatic sites.
For the biopharma industry, this NDA acceptance exemplifies the growing trend of international precision medicine companies targeting Asia's rapidly expanding oncology diagnostics market. Telix's approach integrates robust local clinical data with global standards, addressing regulatory expectations while confirming product efficacy in Chinese populations. The company's commitment to building its product portfolio and international operations further supports its focus on oncology and rare diseases, potentially transforming prostate cancer management in China.
Industry analysts view this as a positive signal for Telix's Asia-Pacific expansion, particularly given the rising demand for innovative imaging agents amid China's aging population and increasing healthcare spending. The NMPA's acceptance process now moves forward, with Telix and Grand Pharma collaborating closely to expedite review. Successful approval could significantly bolster Telix's commercial footprint, contributing to revenue diversification and reinforcing its leadership in radiopharmaceuticals.
Looking ahead, Telix continues to advance its pipeline, including planned resubmissions for other candidates like TLX101-Px and TLX250-Px. This NDA milestone not only validates Illuccix's safety and efficacy profile but also sets a precedent for future regulatory filings in China. As precision medicine gains traction in Asian markets, partnerships like Telix-Grand Pharma demonstrate effective strategies for navigating complex regulatory landscapes while delivering innovative solutions to unmet clinical needs.
The biopharma sector in China is poised for robust growth, with innovative diagnostics playing a pivotal role. Illuccix's potential launch would enhance access to PSMA-PET imaging, improving diagnostic accuracy and patient outcomes. This development underscores the importance of localized clinical evidence in securing regulatory nods and positions Telix advantageously in one of the world's largest pharmaceutical markets.
